Tag: heart failure

Mechanisms of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure

Announcing a new article publication for Cardiovascular Innovations and Applications journal.    Heart failure is an end stage cardiac disease that has been associated with high mortality and rehospitalization rates in previous decades, in spite of standard anti-heart failure therapy, thus posing a major social and economic burden on public health.

Several studies have demonstrated that sodium-glucose cotransporter 2 inhibitors (SGLT2i), anti-hyperglycemic drugs whose function is independent of islet function, have significant positive effects on prognosis and quality of life, by decreasing mortality and readmission rates in patients with heart failure.

To increase general clinicians’ understanding and facilitate the practical application of SGLT2i in the treatment of heart failure, the mechanisms through which SGLT2i alleviate heart failure are reviewed in this article.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0028

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Jiangjun Wei and Jianlin Du. Mechanisms of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0028

Loading

Call for Papers

You are invited to submit an article to Cardiovascular Innovations and Applications (CVIA).

Cardiovascular Innovations and Applications (CVIA) seeks to publish focused articles and original clinical research that explore novel developments in cardiovascular disease, effective control and rehabilitation in cardiovascular disease, and promote cardiovascular innovations and applications for the betterment of public health globally. The journal publishes basic research that has clinical applicability to promote timely communication of the latest insights relating to coronary artery disease, heart failure, hypertension, cardiac arrhythmia, prevention of cardiovascular disease with a heavy emphasis on risk factor modification.

CVIA was launched in 2015 as an open access journal, offering high visibility and discoverability through its open access publishing approach. As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, CVIA will actively support authors through open access publishing and through waiving author fees.  

The journal welcomes the following article types:

  • Editorials
  • Original Research
  • Review Articles
  • Commentaries
  • Case Reports
  • Case Studies
  • Methodology papers related to clinical trials
  • Letters to the Editor

For more information on our journal please see the CVIA website https://cvia-journal.org/; recently published content is available on ScienceOpen  https://www.scienceopen.com/search#collection/32b77252-732d-468f-a6f9-9637d4762967 .

Submissions to Cardiovascular Innovations and Applications (CVIA) can be made using ScholarOne, the online submission and peer review system. Registration and access is available at https://mc04.manuscriptcentral.com/cvia-journal. There are no author submission or article processing fees.

CVIA is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ and Index Copernicus Databases.

Follow CVIA on Twitter @CVIA_Journal; or Facebook https://www.facebook.com/cvia.journal/.

Articles of interest include:

Psychosocial Risk Factors and Cardiovascular Disease: Epidemiology, Screening, and Treatment Considerations

Novel SPECT Technologies and Approaches in Cardiac Imaging

Global Burden of Cardiovascular Disease

Clinical Characteristics and Durations of Hospitalized Patients with COVID-19 in Beijing: A Retrospective Cohort Study

Rationale and Design of the Randomized Controlled Trial of Intensive Versus Usual ECG Screening for Atrial Fibrillation in Elderly Chinese by an Automated ECG System in Community Health Centers in Shanghai (AF-CATCH)

The Effect of Home-Based Cardiac Rehabilitation on Functional Capacity, Behavior, and Risk Factors in Patients with Acute Coronary Syndrome in China

Current Management Strategies in Patients with Heart Failure and Atrial Fibrillation: A Review of the Literature

Telemedicine: Its Importance in Cardiology Practice. Experience in Chile

Management of Hypertension: JNC 8 and Beyond

The Relationship Between Mean Platelet Volume and In-Hospital Mortality in Geriatric Patients with ST Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention

Loading

CVIA has just published the first issue of Volume 6

Highlighted papers in the issue are as follows:

Efficacy and Renal Tolerability of Ultrafiltration in Acute Decompensated Heart Failure: A Meta-analysis and Systematic Review of 19 Randomized Controlled Trials

 By Yajie Liu and Xin Yuan (DOI 10.15212/CVIA.2021.0020).

In this important Review paper, the authors discuss, the importance of acute decompensated heart failure (ADHF)  which is a life-threatening and costly disease. Controversy remains regarding the efficacy and renal tolerability of ultrafiltration for treating ADHF.  The authors performed a meta-analysis to evaluate this clinical issue. A search of PubMed, EMBASE, and the Cochrane database of controlled trials was performed from inception to March 2021 for relevant randomized controlled trials. The quality of the included trials and outcomes was evaluated with the use of the risk of bias assessment tool and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, respectively. The risk ratio and the standardized mean difference (SMD) or weighted mean difference (WMD) were computed and pooled with fixed-effects or random-effects models. Results: This meta-analysis included 19 studies involving 1281 patients. Ultrafiltration was superior to the control treatments for weight loss (WMD 1.24 kg, 95% confidence interval [CI] 0.38–2.09 kg, P = 0.004) and fluid removal (WMD 1.55 L, 95% CI 0.51–2.59 l, P = 0.003) and was associated with a significant increase in serum creatinine level compared with the control treatments (SMD 0.15 mg/dL, 95% CI 0.00–0.30 mg/dL, P = 0.04). However, no significant effects were found for serum N-terminal prohormone of brain natriuretic peptide level, length of hospital stay, all-cause mortality, or all-cause rehospitalization in the ultrafiltration group. Conclusions: The use of ultrafiltration in patients with ADHF is superior to the use of the control treatments for weight loss and fluid removal but has adverse renal effects and lacks significant effects on long-term prognosis, indicating that this approach to decongestion in ADHF patients is efficient for fluid management but less safe renally.

Clinical Characteristics and Durations of Hospitalized Patients with COVID-19 in Beijing: A Retrospective Cohort Study

By Wen Zhao, Xiangyi Zha, Ning Wang, Dongzeng Li, Aixin Li and Shikai Yu (DOI 10.15212/CVIA.2021.0019)

In this important research paper, the authors provide information on clinical characteristics and different durations of COVID-19 and identify the potential risk factors for longer hospitalization of patients with COVID-19. In this retrospective study, the researchers enrolled 77 patients (age 52 ± 20 years; 44.2% males) with laboratory confirmed COVID-19 admitted to Beijing YouAn Hospital between January 21 and February 8, 2020. Epidemiological, clinical, and radiological data on admission were collected; complications and outcomes were followed up until February 26, 2020. The end point of the study was discharge alive within 2 weeks. Cox proportional-hazards regression was performed to identify risk factors for longer hospitalization. Results: Of 77 patients, there were 34 males (44.2%), 24 (31.2%) with comorbidities, 22 (28.6%) with lymphopenia, 20 (26.0%) with severe COVID-19, and 28 (36.4%) with complications. By the end of follow-up, 64 patients (83.1%) were discharged home, eight remained in hospital, and five had died. Thirty-six patients (46.8%) were discharged within 14 days and thus reached the study end point, including 34 of the 57 patients with nonsevere COVID-19 (59.6%) and two of the 20 patients with severe COVID-19 (10%). The overall cumulative probability of the end point was 48.3%. Hospital length of stay and the duration from exposure to discharge for the 64 discharged patients were 13 (10–16.5) days and 23 (18–24.5) days, respectively. A multivariable stepwise Cox regression model showed that bilateral pneumonia on CT scan, shorter time from illness onset to admission, severity of disease, and lymphopenia were independently associated with longer hospitalization. Conclusions: COVID-19 has a shorter duration of disease and hospital length of stay than severe acute respiratory syndrome. Bilateral pneumonia on CT scan, shorter period from illness onset to admission, lymphopenia, and severity of disease are the risk factors for longer hospitalization of patients with COVID-19.

CTO (Chronic Total Occlusion)

By Charles Richard Conti and Calvin Choi (DOI 10.15212/CVIA.2021.0015)

In this important Commentary paper,  the authors consider the problem of CTO. There are no studies in patients with non-viable myocardium subtending a CTO to show improvement of regional wall motion after opening of the CTO. Patients without symptomatic multivessel CAD or no symptoms of angina have not been evaluated since there was no indication for study in the catheterization laboratory. CTO of collateral vessels that feed viable myocardium may lead to improvement in regional

myocardial wall motion and thus potentially a decrease in mortality. CTO recanalization in patients with active angina improve symptoms despite limited ability to demonstrate an improvement in wall motion.

Loading

Continuous Flow Left Ventricular Assist Device Therapy

Continuous Flow Left Ventricular Assist Device Therapy: A Focused Review on Optimal Patient Selection and Long-Term Follow-up Using Echocardiography

Authors: Vilaro, Juan R.; Szady, Anita; Ahmed, Mustafa M.; Dawson, Jacqueline; Aranda, Juan M.

Despite widespread awareness and use of scientifically proven life-prolonging medical and device-based therapies over the last two decades, heart failure remains a leading cause of morbidity, mortality, and health care expenditure in the United States. Mechanical circulatory support with a continuous-flow left ventricular assist device (CF-LVAD), either as a bridge to heart transplantation or as destination therapy, is an increasingly used treatment modality for patients with advanced heart failure syndromes that worsen despite their receiving standard therapies. CF-LVAD support creates unique hemodynamic alterations that must be understood to provide appropriate care for these patients before and after implantation. Echocardiography is essential in the evaluation of patients who are being considered for or are mechanically supported by CF-LVADs. Here we provide a focused clinical review on the use of echocardiography in two main aspects of the evaluation of these patients: (a) optimal patient selection for CF-LVAD support and (b) follow-up assessment of optimal pump function.

Document Type: Research Article

DOI: http://dx.doi.org/10.15212/CVIA.2015.0013

Loading

Evaluation of the Heart Failure Patient by Echocardiography

The Evaluation of the Heart Failure Patient by Echocardiography: Time to go beyond the Ejection Fraction

Authors: Dowe, Jacqueline Dawson; Vilaro, Juan; Hamilton, Karen; Szady, Anita; Aranda, Juan M.

Heart failure is a complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. The echocardiogram is the single most performed and useful study in these patients. This article reviews the role of the echocardiogram in the evaluation of the heart failure patient, without focusing on the left ventricle. The discussion includes the use of the echocardiogram in the assessment of the right ventricle and diastolic function and in detecting hemodynamic and morphologic changes in heart failure over a period of time. In addition, we highlight some of the limitations of echocardiography in the assessment of these patients.

Document Type: Research Article

DOI: http://dx.doi.org/10.15212/CVIA.2015.0008

Loading

Noninvasive Hemodynamic Monitoring for Heart Failure

Noninvasive Hemodynamic Monitoring for Heart Failure: A New Era of Heart Failure Management

Authors: Hernandez, Gabriel A.; Navas, Viviana; Chaparro, Sandra

Despite the development of noninvasive tools as echocardiography, right-sided heart catheterization remains an integral part of the cardiovascular evaluation. In the last decade, better understanding of the hemodynamic process before heart failure decompensation led to improvement of outpatient strategies to prevent it. Advances in implantable wireless technology now allow frequent and direct measurement of intracardiac filling pressures, which can be monitored by health care providers to help tailor therapy to reduce filling pressures and hospital readmission rates.

Document Type: Research Article

DOI: http://dx.doi.org/10.15212/CVIA.2015.0009

Loading

Epidemiological Study of Heart Failure in China

Epidemiological Study of Heart Failure in China

Authors: Guo, Yang; Zhao, Dong; Liu, Jing

Heart failure (HF) is a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood. HF is one of the most important and severe end stages of many cardiovascular diseases. Epidemiological studies of HF have focused mainly on the prevalence, incidence, mortality, fatality, and distribution and temporal trends of these indicators among different populations. This review highlights important epidemiological studies of HF in China.

Loading

Cardiac Sarcoidosis

Cardiac Sarcoidosis: Sorting Fact from Fiction in This Rare Cardiomyopathy

Authors: Rajapreyar, Indranee; Langlois, Elizabeth

Sarcoidosis is a rare condition of granulomatous infiltration of many tissues of the body, including the heart. Cardiac sarcoidosis has been challenging to study, as it is often asymptomatic, although the initial presentation can be sudden cardiac death. The incidence and prevalence rates have been difficult to establish and no expert agreed upon guidelines for diagnosis and management of cardiac sarcoidosis exist, and clinical manifestations are varied. The pathophysiology of granuloma formation in the myocardium as well as other tissues is governed by immune response to some environmental antigen. Genetics is also thought to play a role, although gene alterations have not been extensively studied, and no specific set of genetic mutations has been identified to aid in identification of individuals at risk of developing disease. Epigenetic factors likely play a significant role in modulation of gene expression with respect to immune response. There is no standardized screening tool for the identification of cardiac sarcoidosis. The presence of systemic sarcoidosis and new-onset third-degree heart block or ventricular arrhythmias warrants further investigation for cardiac sarcoidosis. MRI and PET are useful in helping to identify cardiac sarcoidosis but are not stand-alone tests. Endomyocardial biopsy is the gold standard but has a low yield owing to the patchy nature of granuloma formation in the myocardium. Therapy should be instituted early and involves immunosuppressive therapy with predominant use of corticosteroids. Arrhythmias, either ventricular or high-grade heart blocks, are managed with device therapy. Clinical presentation may warrant use of antiarrhythmic agents and/or catheter ablation. Survival and disease prognosis are dependent on early diagnosis and treatment. This review details the current understanding of cardiac sarcoidosis and highlights diagnostic strategies and treatment with the aim of guiding the clinician to early identification of patients and implementation of appropriate management in this rare disease entity.

Loading

Unusual Cardiomyopathies

Unusual Cardiomyopathies: Some May Be More Usual Than Previously Thought and Simply Underdiagnosed

Loading

Heart Failure Issues and Management: A European Perspective

Loading